Growth failure associated with sirolimus: case report.
作者： Gloria A. Rangel , Gema Ariceta
DOI: 10.1007/S00467-009-1215-9
关键词: Kidney transplantation 、 Body surface area 、 Renal function 、 Nephrology 、 Medicine 、 Internal medicine 、 Calcineurin 、 Growth velocity 、 Endocrinology 、 Urology 、 Sirolimus 、 Linear growth
摘要: An 11-year-old girl, who was a renal transplant recipient, developed linear growth failure associated in time with sirolimus (SRL) treatment. After 5 years of functional graft [creatinine clearance (CCr) 90 ml/min per 1.73 m2 body surface area], she acute due to calcineurin inhibitor-related hemolytic uremic syndrome, and cyclosporine A replaced by SRL. Before the drug change, had been growing normally (5.5 cm/year) reached 33.9 percentile (P) height (z-height −0.41), similar her target. Two later, decreased P 6th −1.54), as velocity diminished 2.2 cm/year, despite optimal function (CCr 68 m2). Human recombinant hormone needed promote catch-up achieve 49th −0.03). SRL may have deleterious effects on children its characteristic anti-proliferative anti-angiogenic properties. Pediatric recipients’ should be cautiously monitored while they are being given
springer.com
sci-hub.se 参考文章(18)
Sirolimus in pediatric solid organ transplantation. Pediatric Transplantation. ,vol. 9, pp. 427- 429 ,(2005) , 10.1111/J.1399-3046.2005.00385.X
Britta Höcker, Reinhard Feneberg, Sabine Köpf, Lutz T. Weber, Rüdiger Waldherr, Elke Wühl, Burkhard Tönshoff, SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatric Transplantation. ,vol. 10, pp. 593- 601 ,(2006) , 10.1111/J.1399-3046.2006.00526.X
C.D. Garcia, V.B. Bittencourt, A.B. Alves, V.D. Garcia, A. Tumelero, J.S. Antonello, D. Malheiros, Conversion to Sirolimus in Pediatric Renal Transplantation Recipients Transplantation Proceedings. ,vol. 38, pp. 1901- 1903 ,(2006) , 10.1016/J.TRANSPROCEED.2006.06.063
Vikas R. Dharnidharka, Gary Stevens, Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatric Transplantation. ,vol. 9, pp. 622- 626 ,(2005) , 10.1111/J.1399-3046.2005.00361.X
Oscar Alvarez-Garcia, Eduardo Carbajo-Pérez, Enrique Garcia, Helena Gil, Ines Molinos, Julian Rodriguez, Flor A. Ordoñez, Fernando Santos, Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatric Nephrology. ,vol. 22, pp. 954- 961 ,(2007) , 10.1007/S00467-007-0456-8
Leonard C. Hymes, Barry L. Warshaw, Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatric Transplantation. ,vol. 9, pp. 520- 522 ,(2005) , 10.1111/J.1399-3046.2005.00324.X
A Franco, D Hernandez, L Capdevilla, P Errasti, M Gonzalez, JC Ruiz, J Sanchez, HUS-Sirolimus Spanish Study Group, None, De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Congress of the Catalan Transplantation Society. ,vol. 35, pp. 1764- 1766 ,(2003) , 10.1016/S0041-1345(03)00614-6
Richard N. Fine M.D., Donald Stablein, Arthur H. Cohen, Amir Tejani, Edward Kohaut, Recombinant human growth hormone post-renal transplantation in children: A randomized controlled study of the NAPRTCS Kidney International. ,vol. 62, pp. 688- 696 ,(2002) , 10.1046/J.1523-1755.2002.00489.X
R El-Sabrout, R Weiss, F Butt, I Rashid, V Delaney, M Qadir, P Hanson, K Butt, Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. International Congress on Immunosuppression. ,vol. 34, pp. 1946- 1947 ,(2002) , 10.1016/S0041-1345(02)03132-9
G. Guest, E. Bérard, H. Crosnier, T. Chevallier, R. Rappaport, M. Broyer, Effects of growth hormone in short children after renal transplantation Pediatric Nephrology. ,vol. 12, pp. 437- 446 ,(1998) , 10.1007/S004670050483